Abstract
T-cell acute lymphoblastic leukemia (ALL) accounts for 15% of ALL cases in children and has been associated with a worse prognosis. Cytogenetic studies show an abnormal karyotype in 50-60% of the T-cell ALL patients; ABL1 fusions are present in approximately 8% of the cases. Dasatinib, a second-generation tyrosine kinase inhibitor, directly targets the BCR-ABL gene. We describe a pediatric case of T-cell ALL with amplification of the ABL1 gene in which remission was achieved only after the addition of dasatinib to conventional chemotherapy.
Original language | English (US) |
---|---|
Pages (from-to) | 333-334 |
Number of pages | 2 |
Journal | Pediatric Blood and Cancer |
Volume | 59 |
Issue number | 2 |
DOIs | |
State | Published - Aug 2012 |
Keywords
- ABL1 amplification
- Acute lymphoblastic leukemia
- Dasatinib
- Leukemia treatment
- T-cell ALL
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology